RxDoctor Payments Data

Meghan Peters, PA

Medical · Kansas City, KSNPI 1922566330

Payments from drug & device makers

$1,116in general payments, 2019–2025

Across 38 payments — averaging $29.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$693
  • Antares Pharma, Inc.$103
  • Tandem Diabetes Care, Inc.$62
  • Lilly USA, LLC$49
  • Medtronic$46
  • Novartis$40
  • plus $123 from 7 others

What the payments were for

  • Food & beverage$1,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,116 in reported general payments places this provider in the 55th percentile of 205 medical providers in Kansas.

See all medical providers in Kansas

Medicare billing

Part B allowed, 2024
$49,196
Medicare patients
251
Services billed
758

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide254$408,654
JardianceEmpagliflozin193$256,514
MounjaroTirzepatide192$229,214
TrulicityDulaglutide78$97,984
Tresiba Flextouch U-200Insulin Degludec63$51,160
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$45,289
FarxigaDapagliflozin Propanediol34$43,848
Fiasp FlextouchInsulin Aspart (Niacinamide)25$41,115
Novolog FlexpenInsulin Aspart101$35,139
Humalog Kwikpen U-100Insulin Lispro54$27,884
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/715$20,774
NovologInsulin Aspart42$18,637
Tresiba Flextouch U-100Insulin Degludec35$18,429
Lantus SolostarInsulin Glargine,hum.Rec.Anlog102$17,931
Insulin Lispro Kwikpen U-100Insulin Lispro34$14,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$16$427,291296 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$49$337,111289 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 205 medical providers in Kansas.

Other medical in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →